Annual Cash & Cash Equivalents
$111.70 M
-$530.90 M-82.62%
31 December 2023
Summary:
Emergent BioSolutions annual cash & cash equivalents is currently $111.70 million, with the most recent change of -$530.90 million (-82.62%) on 31 December 2023. During the last 3 years, it has fallen by -$509.60 million (-82.02%). EBS annual cash & cash equivalents is now -82.62% below its all-time high of $642.60 million, reached on 31 December 2022.EBS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$149.90 M
+$80.20 M+115.06%
30 September 2024
Summary:
Emergent BioSolutions quarterly cash and cash equivalents is currently $149.90 million, with the most recent change of +$80.20 million (+115.06%) on 30 September 2024. Over the past year, it has increased by +$62.10 million (+70.73%). EBS quarterly cash and cash equivalents is now -76.67% below its all-time high of $642.60 million, reached on 31 December 2022.EBS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -82.6% | +70.7% |
| 3 y3 years | -82.0% | -62.9% |
| 5 y5 years | -0.5% | +7.7% |
EBS Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -82.6% | at low | -76.7% | +115.1% |
| 5 y | 5 years | -82.6% | at low | -76.7% | +115.1% |
| alltime | all time | -82.6% | +2183.8% | -76.7% | +2097.6% |
Emergent BioSolutions Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $149.90 M(+115.1%) |
| June 2024 | - | $69.70 M(-11.2%) |
| Mar 2024 | - | $78.50 M(-29.7%) |
| Dec 2023 | $111.70 M(-82.6%) | $111.70 M(+27.2%) |
| Sept 2023 | - | $87.80 M(-0.9%) |
| June 2023 | - | $88.60 M(-79.4%) |
| Mar 2023 | - | $430.20 M(-33.1%) |
| Dec 2022 | $642.60 M(+11.5%) | $642.60 M(+166.7%) |
| Sept 2022 | - | $240.90 M(-32.7%) |
| June 2022 | - | $358.10 M(-17.8%) |
| Mar 2022 | - | $435.80 M(-24.4%) |
| Dec 2021 | $576.10 M(-7.3%) | $576.10 M(+42.7%) |
| Sept 2021 | - | $403.80 M(-9.8%) |
| June 2021 | - | $447.50 M(-18.3%) |
| Mar 2021 | - | $547.80 M(-11.8%) |
| Dec 2020 | $621.30 M(+270.3%) | $621.30 M(+49.7%) |
| Sept 2020 | - | $415.00 M(+54.4%) |
| June 2020 | - | $268.80 M(+48.1%) |
| Mar 2020 | - | $181.50 M(+8.2%) |
| Dec 2019 | $167.80 M(+49.6%) | $167.80 M(+20.5%) |
| Sept 2019 | - | $139.20 M(-21.5%) |
| June 2019 | - | $177.40 M(+29.3%) |
| Mar 2019 | - | $137.20 M(+22.3%) |
| Dec 2018 | $112.20 M(-37.1%) | $112.20 M(-66.9%) |
| Sept 2018 | - | $339.36 M(+78.4%) |
| June 2018 | - | $190.24 M(+16.3%) |
| Mar 2018 | - | $163.61 M(-8.2%) |
| Dec 2017 | $178.30 M(-34.3%) | $178.30 M(-47.7%) |
| Sept 2017 | - | $340.99 M(+8.0%) |
| June 2017 | - | $315.63 M(+16.8%) |
| Mar 2017 | - | $270.17 M(-0.5%) |
| Dec 2016 | $271.51 M(-11.9%) | $271.51 M(-9.2%) |
| Sept 2016 | - | $298.93 M(-10.3%) |
| June 2016 | - | $333.39 M(-2.2%) |
| Mar 2016 | - | $341.02 M(+10.6%) |
| Dec 2015 | $308.30 M | $308.30 M(-0.1%) |
| Sept 2015 | - | $308.72 M(+43.7%) |
| June 2015 | - | $214.84 M(-0.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $216.51 M(-22.8%) |
| Dec 2014 | $280.50 M(+56.4%) | $280.50 M(+15.8%) |
| Sept 2014 | - | $242.25 M(+44.1%) |
| June 2014 | - | $168.13 M(+4.9%) |
| Mar 2014 | - | $160.22 M(-10.7%) |
| Dec 2013 | $179.34 M(+26.6%) | $179.34 M(+3.9%) |
| Sept 2013 | - | $172.56 M(+10.4%) |
| June 2013 | - | $156.24 M(+20.0%) |
| Mar 2013 | - | $130.24 M(-8.1%) |
| Dec 2012 | $141.67 M(-1.6%) | $141.67 M(-28.4%) |
| Sept 2012 | - | $197.90 M(+22.3%) |
| June 2012 | - | $161.84 M(+7.6%) |
| Mar 2012 | - | $150.43 M(+4.5%) |
| Dec 2011 | $143.90 M(-14.9%) | $143.90 M(+14.8%) |
| Sept 2011 | - | $125.35 M(+2.7%) |
| June 2011 | - | $122.09 M(-10.8%) |
| Mar 2011 | - | $136.93 M(-19.0%) |
| Dec 2010 | $169.02 M(+64.2%) | $169.02 M(+11.8%) |
| Sept 2010 | - | $151.23 M(+48.0%) |
| June 2010 | - | $102.19 M(-12.2%) |
| Mar 2010 | - | $116.38 M(+13.1%) |
| Dec 2009 | $102.92 M(+12.5%) | $102.92 M(-13.3%) |
| Sept 2009 | - | $118.78 M(+15.9%) |
| June 2009 | - | $102.51 M(+67.0%) |
| Mar 2009 | - | $61.38 M(-32.9%) |
| Dec 2008 | $91.47 M(-13.5%) | $91.47 M(-12.6%) |
| Sept 2008 | - | $104.69 M(+24.6%) |
| June 2008 | - | $84.01 M(-9.4%) |
| Mar 2008 | - | $92.75 M(-12.3%) |
| Dec 2007 | $105.73 M(+38.4%) | $105.73 M(+335.7%) |
| Sept 2007 | - | $24.27 M(-28.6%) |
| June 2007 | - | $33.98 M(-49.8%) |
| Mar 2007 | - | $67.64 M(-11.5%) |
| Dec 2006 | $76.42 M(+110.6%) | $76.42 M(+283.9%) |
| Sept 2006 | - | $19.91 M(-45.2%) |
| Dec 2005 | $36.29 M(+432.1%) | $36.29 M(+432.1%) |
| Dec 2004 | $6.82 M(+39.5%) | $6.82 M |
| Dec 2002 | $4.89 M(-16.5%) | - |
| Dec 2001 | $5.85 M | - |
FAQ
- What is Emergent BioSolutions annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Emergent BioSolutions?
- What is Emergent BioSolutions annual cash & cash equivalents year-on-year change?
- What is Emergent BioSolutions quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly cash and cash equivalents year-on-year change?
What is Emergent BioSolutions annual cash & cash equivalents?
The current annual cash & cash equivalents of EBS is $111.70 M
What is the all time high annual cash & cash equivalents for Emergent BioSolutions?
Emergent BioSolutions all-time high annual cash & cash equivalents is $642.60 M
What is Emergent BioSolutions annual cash & cash equivalents year-on-year change?
Over the past year, EBS annual cash & cash equivalents has changed by -$530.90 M (-82.62%)
What is Emergent BioSolutions quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of EBS is $149.90 M
What is the all time high quarterly cash and cash equivalents for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly cash and cash equivalents is $642.60 M
What is Emergent BioSolutions quarterly cash and cash equivalents year-on-year change?
Over the past year, EBS quarterly cash and cash equivalents has changed by +$62.10 M (+70.73%)